Asthma is a chronic airway disease with recurrent symptoms of wheezing, chest tightness, dyspnea, and cough. Asthma is characterized by airway inflammation, airflow obstruction, and variable respiratory symptoms.1 The 2007 Expert Panel Report-3 Guidelines for the Diagnosis and Management of Asthma1 suggest a stepwise approach for managing asthma based on symptom severity. The stepwise approach consists of escalating or deescalating asthma therapy as needed to control symptoms and prevent adverse asthma outcomes, such as exacerbations and accelerated loss of lung function. Traditionally, chronic asthma treatments have been categorized as relievers, short-acting β2-agonists (SABAs; eg, albuterol) used to acutely relieve symptoms, and controllers, inhaled corticosteroids (ICSs) and ICSs in combination with long-acting β2-agonists (LABAs) used daily to prevent symptoms, reduce exacerbations, and improve lung function. Recently, this paradigm of asthma management has been challenged by evidence supporting novel approaches using conventional controller medications (Box).
Tripple JW, Ameredes BT, Calhoun WJ. Outpatient Management of Chronic Asthma in 2020. JAMA. 2020;323(6):561–562. doi:10.1001/jama.2019.19986
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: